Abstract 152P
Background
Neoadjuvant chemoradiotherapy (nCRT) is the standard initial treatment for locally advanced rectal cancer (LARC) to reduce tumor size before surgery. Although some patients achieve complete pathological response and become eligible for organ-preserving strategies, predicting nCRT response remains challenging. The intratumoral genetic heterogeneity (ITGH) has emerged as a potential biomarker in LARC patients. Tumor-infiltrating lymphocytes (TILs) enriched with cytotoxic CD8+ T-cells indicate better prognosis and treatment response. An immunohistochemistry-based score, estimating CD3+ and CD8+ enrichment in LARC TILs, is proposed as a predictive test. Elements from anti-tumoral immune response could serve as potential predictive biomarkers.
Methods
We analyzed 80 primary LARC tumors (18 responders, nCRT-R, versus nonresponders 62, nCRT-NR) through WXS and TCRseq. We evaluated nCRT response, tumor mutation burden (TMB), neoantigen load (NAL), HLA polymorphism, somatic mutation, TCR diversity/clonality, ITGH levels, and DNA mismatch repair deficiency.
Results
We identified six significantly mutated genes (KRAS, APC, TP53, FBXW7, ARID1A, SLITRK6) (p<0.05; FDR<=0.1). Somatic mutations in driver genes, 23 dMMR genes, and COSMIC somatic signatures S6, S15, S20, or S26 did not show any association with nCRT response (p>0.5; Fisher Test). We measured ITGH through MATH score, but no significant difference between nCRT-R and NR (p=0.8; Wilcoxon test) was observed. TMB and NAL were significantly higher in nCRT-NR (p<0.05). HLA somatic mutation did not have a significant impact on antigen presentation and treatment response (8 mutations in 8 patients; Pearson Chi-squared, p=0.76). HLA polymorphism was not relevant (Pearson Chi-squared, p=0.64). Finally, nCRT response was not associated with TCR Shannon diversity or clonality (Wilcoxon test, p=0.25 and p=0.48, respectively); however, we could not quantify CD8+ T-cells.
Conclusions
Gene driver signature, ITGH, or dMMR mutations/signatures were not predictive biomarkers of nCRT response; however, preliminary findings suggest a subset of highly immunogenic nCRT-NR LARCs patients could benefit from immunotherapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
R. Perez.
Funding
FAPESP: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract